CXL could treat stages of keratoconus

Article

Corneal collagen crosslinking (CXL) could successfully treat certain stages of keratoconus, according to a recent published paper.

Corneal collagen crosslinking (CXL) could successfully treat certain stages of keratoconus, according to a recent published paper.

Dr Ziad Hassan et al., Orbident Refractive Surgery and Medical Centre, Medical and Health Science Center, Debrecen, Hungary, treated a total of 38 eyes of 25 patients with the CXL technique. The team performed slit-lamp examination tests, visual acuity tests and pachymetry measurements on all eyes. Corneal topography was used to obtain numerical data. The group also used simulated keratometry (K1, K2), cylinder value (CYL), surface asymmetry index (SAI), irregular astigmatism index (IAI), surface regulatory index (SRI), average corneal power (ACP), and corneal eccentricity index (CEI).

There were no significant changes in the values of mean K1, cylinder, SAI, IAI, SRI, K2 and CEI at the end of the examination period. Uncorrected visual acuity did not change, but best-corrected visual acuity changed from 0.21 ± 0.17 to 0.12 ± 0.11 in logMAR scale. However, this was not significant.

There were no changes in intraocular pressure, the cornea remained clear during the follow-up period and there were no occurrences of corneal thinning. CXL can offer a way to prevent progression in keratometric indices.

To read the abstract please visit the European Journal of Ophthalmology.

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.